TV Presenter & Finance EditorTV presenter and finance editor at Grafa, with a Master’s in Commerce from UWA and diverse industry experience in finance, insurance, and media.
Monadelphous Group (ASX:MND) has secured a major long-term maintenance services contract with mining giant Rio Tinto (ASX:RIO), valued at approximately $300 million over five years.
3D Energi (ASX:TDO) has announced a gas discovery at the Charlemont-1 exploration well within the VIC/P79 permit, offshore Victoria, where it holds a 20% interest.
Proteomics International Laboratories (ASX:PIQ) has appointed David Morris as CEO and Managing Director, effective Jan. 19.
Australian medicinal cannabis leaders Little Green Pharma (ASX:LGP) and Cannatrek have entered into a binding scheme implementation deed, under which LGP will acquire 100% of Cannatrek’s issued capital via a scheme of arrangement.
AVITA Medical (ASX:AVH) reported preliminary unaudited results for the fourth quarter and full year of fiscal 2025, highlighting year-on-year revenue growth, a new US$60 million debt facility, and a positive revenue outlook for 2026.
Meta Platforms (NASDAQ:META) and EssilorLuxottica are in discussions to double their production capacity for AI-powered smart glasses to 20 million units annually by the end of 2025, according to people familiar with the matter.
Franklin Templeton has updated two long-standing institutional money market funds to support stablecoin reserves and onchain cash activity without creating new crypto-native products.
The Baldwin Group (NASDAQ:BWIN) announced Tuesday the completion of its acquisition of Creisoft, better known as Obie, a Chicago-based insurtech pioneer.
AudioEye (NASDAQ:AEYE) announced Tuesday its 40th consecutive period of record revenue, signaling that the global push for digital accessibility continues to fuel the company’s expansion.
BriaCell Therapeutics Corp. (NASDAQ:BCTX) announced Tuesday that the first patient in its Bria-OTS trial achieved an 11-month sustained complete resolution of a lung metastasis, providing a significant early validation for the company’s personalized "off-the-shelf" immunotherapy platform.
